INCY
Price
$71.98
Change
-$0.39 (-0.54%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
13.86B
29 days until earnings call
REGN
Price
$690.72
Change
-$26.18 (-3.65%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
75.92B
20 days until earnings call
Ad is loading...

INCY vs REGN

Header iconINCY vs REGN Comparison
Open Charts INCY vs REGNBanner chart's image
Incyte
Price$71.98
Change-$0.39 (-0.54%)
Volume$28.57K
Capitalization13.86B
Regeneron Pharmaceuticals
Price$690.72
Change-$26.18 (-3.65%)
Volume$5.43K
Capitalization75.92B
INCY vs REGN Comparison Chart
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. REGN commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a StrongBuy and REGN is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (INCY: $71.93 vs. REGN: $690.87)
Brand notoriety: INCY and REGN are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 77% vs. REGN: 92%
Market capitalization -- INCY: $13.86B vs. REGN: $75.92B
INCY [@Biotechnology] is valued at $13.86B. REGN’s [@Biotechnology] market capitalization is $75.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $374.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 0 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 0 green, 5 red.
According to our system of comparison, INCY is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 3 TA indicator(s) are bullish while REGN’s TA Score has 3 bullish TA indicator(s).

  • INCY’s TA Score: 3 bullish, 5 bearish.
  • REGN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, REGN is a better buy in the short-term than INCY.

Price Growth

INCY (@Biotechnology) experienced а -1.72% price change this week, while REGN (@Biotechnology) price change was -5.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.85%. For the same industry, the average monthly price growth was -2.06%, and the average quarterly price growth was -3.70%.

Reported Earning Dates

INCY is expected to report earnings on May 06, 2025.

REGN is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-6.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($75.9B) has a higher market cap than INCY($13.9B). INCY has higher P/E ratio than REGN: INCY (799.22) vs REGN (17.09). INCY YTD gains are higher at: 4.141 vs. REGN (-3.013). REGN has higher annual earnings (EBITDA): 5.5B vs. INCY (365M). REGN has more cash in the bank: 9.8B vs. INCY (1.78B). INCY has less debt than REGN: INCY (36.5M) vs REGN (2.7B). REGN has higher revenues than INCY: REGN (13.8B) vs INCY (4.08B).
INCYREGNINCY / REGN
Capitalization13.9B75.9B18%
EBITDA365M5.5B7%
Gain YTD4.141-3.013-137%
P/E Ratio799.2217.094,677%
Revenue4.08B13.8B30%
Total Cash1.78B9.8B18%
Total Debt36.5M2.7B1%
FUNDAMENTALS RATINGS
INCY vs REGN: Fundamental Ratings
INCY
REGN
OUTLOOK RATING
1..100
196
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
10047
SMR RATING
1..100
8951
PRICE GROWTH RATING
1..100
3964
P/E GROWTH RATING
1..100
191
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (66) in the Biotechnology industry is in the same range as INCY (96). This means that REGN’s stock grew similarly to INCY’s over the last 12 months.

REGN's Profit vs Risk Rating (47) in the Biotechnology industry is somewhat better than the same rating for INCY (100). This means that REGN’s stock grew somewhat faster than INCY’s over the last 12 months.

REGN's SMR Rating (51) in the Biotechnology industry is somewhat better than the same rating for INCY (89). This means that REGN’s stock grew somewhat faster than INCY’s over the last 12 months.

INCY's Price Growth Rating (39) in the Biotechnology industry is in the same range as REGN (64). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.

INCY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for REGN (91). This means that INCY’s stock grew significantly faster than REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYREGN
RSI
ODDS (%)
N/A
Bullish Trend 7 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
64%
Bearish Trend 7 days ago
57%
Momentum
ODDS (%)
Bullish Trend 7 days ago
65%
Bullish Trend 7 days ago
67%
MACD
ODDS (%)
Bullish Trend 7 days ago
62%
N/A
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
63%
Bullish Trend 7 days ago
67%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
63%
Bearish Trend 7 days ago
61%
Advances
ODDS (%)
Bullish Trend 8 days ago
61%
Bullish Trend 7 days ago
63%
Declines
ODDS (%)
Bearish Trend 16 days ago
65%
Bearish Trend 16 days ago
51%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
60%
Bearish Trend 7 days ago
56%
Aroon
ODDS (%)
N/A
Bearish Trend 7 days ago
63%
View a ticker or compare two or three
Ad is loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FBRT12.370.25
+2.06%
Franklin BSP Realty Trust
VRRM25.010.28
+1.13%
Verra Mobility Corp
SEED2.000.01
+0.68%
Origin Agritech Limited
SJT4.510.03
+0.67%
San Juan Basin Royalty Trust UBI
ICLR200.24-17.75
-8.14%
ICON plc

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with AXON. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
-0.61%
AXON - INCY
39%
Loosely correlated
+1.96%
SRPT - INCY
33%
Poorly correlated
+0.34%
ZYME - INCY
33%
Poorly correlated
-2.44%
BMRN - INCY
32%
Poorly correlated
-4.75%
UTHR - INCY
32%
Poorly correlated
+0.50%
More

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with IDYA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-3.63%
IDYA - REGN
41%
Loosely correlated
-1.00%
MTNB - REGN
41%
Loosely correlated
+17.08%
TECH - REGN
39%
Loosely correlated
-2.21%
VRTX - REGN
37%
Loosely correlated
-0.41%
INVA - REGN
36%
Loosely correlated
+0.68%
More